(Q48326227)

10 February 2018

http://europepmc.org/abstract/MED/29291351

title

The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis (English)

1 reference

10 February 2018

http://europepmc.org/abstract/MED/29291351

main subject

steatohepatitis

0 references

Tripartite motif containing 47

1 reference

CYLD lysine 63 deubiquitinase

1 reference

negative regulation of p38MAPK cascade

1 reference

Mitogen-activated protein kinase kinase kinase 7

1 reference

Tripartite motif-containing 47

1 reference

CYLD lysine 63 deubiquitinase

1 reference

author

Zan Huang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Michele Alves-Bezerra

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yan-Xiao Ji

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Xia Yang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Xiaozhan Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ling-Ping Zhao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Pi-Xiao Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Xiao-Jing Zhang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lin Cai

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Peng Zhang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yue-Xin Lu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lan Bai

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Mao-Mao Gao

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Huan Zhao

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Song Tian

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yong Wang

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Zhi-Xiang Huang

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Xue-Yong Zhu

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yan Zhang

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jun Gong

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Zhi-Gang She

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Feng Li

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

David E Cohen

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hongliang Li

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

1 January 2018

1 reference

10 February 2018

http://europepmc.org/abstract/MED/29291351

published in

Nature Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

213-223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29291351%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nm.4461

1 June 2020

exact match

0 references

cites work

NAFLD: a multisystem disease.

1 reference

Nonalcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

21 January 2018

1 reference

NAFLD, NASH and liver cancer

21 January 2018

1 reference

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

21 January 2018

1 reference

Nonalcoholic Steatohepatitis.

21 January 2018

1 reference

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

Ubiquitination in disease pathogenesis and treatment

21 January 2018

1 reference

Ubiquitin chain cleavage: CYLD at work

21 January 2018

1 reference

The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.

21 January 2018

1 reference

Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling

21 January 2018

1 reference

Regulation of T cell development by the deubiquitinating enzyme CYLD

21 January 2018

1 reference

Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation

21 January 2018

1 reference

Gadolinium chloride ameliorates acute lung injury associated with severe acute pancreatitis in rats by regulating CYLD/NF-κB signaling

21 January 2018

1 reference

CYLD Deubiquitinates Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Contributing to Adventitial Remodeling.

21 January 2018

1 reference

Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88.

21 January 2018

1 reference

CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt

21 January 2018

1 reference

Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation

21 January 2018

1 reference

The deubiquitinating enzyme CYLD regulates the differentiation and maturation of thymic medullary epithelial cells

21 January 2018

1 reference

CYLD and the NEMO Zinc Finger Regulate Tumor Necrosis Factor Signaling and Early Embryogenesis

21 January 2018

1 reference

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

Reduced expression of CYLD in human colon and hepatocellular carcinomas

21 January 2018

1 reference

Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner

21 January 2018

1 reference

The tumor suppressor CYLD controls the function of murine regulatory T cells

21 January 2018

1 reference

Cylindromatosis--A Protective Molecule against Liver Diseases

21 January 2018

1 reference

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.

21 January 2018

1 reference

Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.

21 January 2018

1 reference

Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

CYLD-mediated signaling and diseases.

21 January 2018

1 reference

Nonalcoholic Steatohepatitis: A Search for Factual Animal Models

21 January 2018

1 reference

Mitogen-activated protein kinases in innate immunity

21 January 2018

1 reference

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.

21 January 2018

1 reference

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.

21 January 2018

1 reference

Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses

21 January 2018

1 reference

Therapies in non-alcoholic steatohepatitis (NASH).

21 January 2018

1 reference

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

21 January 2018

1 reference

Cell type-specific function of TAK1 in innate immune signaling

21 January 2018

1 reference

TAK1, more than just innate immunity

21 January 2018

1 reference

TAK1 control of cell death

21 January 2018

1 reference

USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity.

21 January 2018

1 reference

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling

21 January 2018

1 reference

The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis

21 January 2018

1 reference

TAK1-dependent autophagy: A suppressor of fatty liver disease and hepatic oncogenesis

21 January 2018

1 reference

TAK1 regulates hepatic cell survival and carcinogenesis

21 January 2018

1 reference

Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.

21 January 2018

1 reference

Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkap

21 January 2018

1 reference

MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.

21 January 2018

1 reference

Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway

21 January 2018

1 reference

Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.

21 January 2018

1 reference

Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis

21 January 2018

1 reference

TRAF1 is a key mediator for hepatic ischemia/reperfusion injury

21 January 2018

1 reference

Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury.

21 January 2018

1 reference

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.

21 January 2018

1 reference

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.

21 January 2018

1 reference

The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases.

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

SCFβ-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination

1 reference